20 February 2023>: Database Analysis
Drug-Induced Cardiotoxicity in Children During the Past 30 Years: A Bibliometric Study and Visualization Analysis
Mingfen Wu 1CDE* , Yang Yang 2BC* , Mingnan Cao 1F , Teng Liu 1B , Yue Tian 1D , Zhigang Zhao 1A , Bin Zhu 1ACF*DOI: 10.12659/MSM.938673
Med Sci Monit 2023; 29:e938673
Supplementary Table 2 Summary of the largest 13 keywords clusters.
Cluster ID | Size | Silhouette | Mean year | Top terms (LSI) | Top terms (long likelihood ratio, LLR) | Top terms (mutual information, MI) |
---|---|---|---|---|---|---|
0 | 66 | 0.831 | 2008 | Genetic polymorphism; leukemia; visualization; children; high risk | oxidative stress; cumulative dose; arterial stiffness; leukemia; protein carbonylation | (11.67, 0.001); oxidative stress (11.67, 0.001); age (7.77, 0.01); DNA damage (7.77, 0.01); association (7.77, 0.01) | Arterial stiffness (0.59); protein carbonylation (0.59); erythrocyte glutathione (0.59); pulse wave analysis (0.59); acetyl-l-carnitine (0.59) |
1 | 54 | 0.839 | 2008 | Cancer; therapy; cardiotoxicity; childhood; doxorubicin | acute lymphoblastic leukemia; leukocyte count; continuous intravenous infusion; congestive heart; radionuclide ventriculography | (7.58, 0.01); side effects (7.58, 0.01); acute lymphoblastic leukemia (5.79, 0.05); cancer (4.44, 0.05); therapy (4.04, 0.05) | beta-agonist-associated myocardial injury (0.62); transgenic mice (0.62); phosphorylation (0.62); prevention (0.62); life support (0.62) |
2 | 52 | 0.821 | 2009 | Inorganic pyrophosphatase; drug; bacillus subtili; calcium; hydride generation | children; overdose; reversal; naloxone; toxicity | (6.69, 0.01); toxicity (6.62, 0.05); hydride generation (5.16, 0.05); sb(iii) (5.16, 0.05); nuclear cardiology (5.16, 0.05) | Hydride generation (0.26); sb(iii) (0.26); nuclear cardiology (0.26); bone marrow transplant (0.26); hypothermia (0.26) |
3 | 51 | 0.777 | 2009 | Childhood cancer; breast cancer; renal cell; long term; pulmonary arterial | late effects; congestive heart failure; genetic susceptibility; haematopoietic cell transplantation; clinical heart | (11.41, 0.001); anthracycline-induced cardiotoxicity (8.37, 0.005); trastuzumab (8.37, 0.005); pharmacogenomics (8.37, 0.005); adult survivor (8.37, 0.005) | Breast cancer patient (0.49); hematopoietic stem cell transplantation (0.49); dna deletion (0.49); congenital heart disease (0.49); late-onset cardiotoxicity (0.49) |
4 | 49 | 0.823 | 2003 | Children; arrhythmia; histamine; duration; refractoriness | plasmodium falciparum; artemisinin resistance; prolonged treatment; drug utilization; clinical pharmacology | (12.06, 0.001); children (8.84, 0.005); torsade de pointe (8.37, 0.005); combination therapy (8.37, 0.005); efficacy (8.37, 0.005) | Liver microsm (0.49); topotecan (0.49); exposure (0.49); human immunodeficiency virus (0.49); cardiac arrhythmias (0.49) |
5 | 49 | 0.821 | 1999 | Lymphoblastic disease; relapsed t-cell; childhood t-cell; t-cell acute lymphoblastic leukemia; refractory leukemia | long-term follow-up; late relapse; ewings sarcoma; neoadjuvant chemotherapy; multidrug resistance | (12.05, 0.001); cytarabine (6.01, 0.05); late relapse (6.01, 0.05); refractory leukemia (6.01, 0.05); aml therapy (6.01, 0.05) | Cytarabine (0.15); late relapse (0.15); refractory leukemia (0.15); aml therapy (0.15); retinoblastoma (0.15) |
6 | 41 | 0.845 | 2004 | Binding; protein; contraction; intracellular free calcium; ryanodine receptor | toxicity; lignocaine; anesthesia; children; pharmacokinetics | (11.89, 0.001); outcomes (5.93, 0.05); drug resistance (5.93, 0.05); tumor cell line (5.93, 0.05); critical care (5.93, 0.05) | Outcomes (0.16); drug resistance (0.16); tumor cell line (0.16); critical care (0.16); biochemical pharmacology (0.16) |
7 | 39 | 0.817 | 2000 | Drug cardiotoxicity; hiv-associated pulmonary hypertension; risk groups; hiv-associated cardiomyopathy; viral myocardial infection | childhood cancer; congestive heart; late potential; recurrent breast cancer; drug cardiotoxicity | (9.99, 0.005); nitric oxide synthase (4.98, 0.05); autoimmunity (4.98, 0.05); angiotensin-converting enzyme inhibition (4.98, 0.05); palliative care (4.98, 0.05) | Nitric oxide synthase (0.29); autoimmunity (0.29); angiotensin-converting enzyme inhibition (0.29); palliative care (0.29); anthracycline cardiotoxicity (0.29) |
8 | 39 | 0.824 | 2003 | Breast cancer; cardiovascular events; incidence rates; toxicity; guinea pig | cardiotoxicity; index; toxicity; guinea pig; soft tissue | (5.24, 0.05); rabbit (5.24, 0.05); leukemia – myelogenous – acute (5.24, 0.05); bupivacaine (5.24, 0.05); colchicine (5.24, 0.05) | icrf 187 (0.25); rabbit (0.25); leukemia – myelogenous – acute (0.25); bupivacaine (0.25); colchicine (0.25) |
9 | 28 | 0.844 | 1996 | Doxorubicin cardiotoxicity; chemotherapy complication; supportive care; poor prognosis leukemia; doppler echocardiography | poor prognosis leukemia; cardiac toxicity; high-risk leukemia; acute lymphoblastic leukemia; doppler echocardiography | (14.81, 0.001); high-risk leukemia (6.36, 0.05); poor prognosis leukemia (6.36, 0.05); drug-related side effects and adverse reactions (6.36, 0.05); chemotherapy complication (6.36, 0.05) | High-risk leukemia (0.12); poor prognosis leukemia (0.12); drug-related side effects and adverse reactions (0.12); chemotherapy complication (0.12); anthracycline chemotherapy (0.12) |
10 | 27 | 0.984 | 2003 | Fractal dimension; cardiac side effects; approximate entropy; tricyclic antidepressants; cognitive function | adverse event; allergic rhinitis; cognitive function; atopic child; fractal dimension | (8.46, 0.005); cetirizine (8.46, 0.005); adverse event (8.46, 0.005); somnolence (8.46, 0.005); spectral (8.46, 0.005) | Approximate entropy (0.03); cetirizine (0.03); adverse event (0.03); somnolence (0.03); spectral (0.03) |
11 | 19 | 0.881 | 2009 | Cancer; exercise echocardiography; doxorubicin; stress; childhood | leukemia; trial; 4 demethoxydaunorubicin idarubicin; metabolite; children | (5.93, 0.05); myohemoglobin (5.93, 0.05); intrathoracic chemotherapy (5.93, 0.05); doxorubicin toxicity (5.93, 0.05); refractory (5.93, 0.05) | Intrapleural chemotherapy (0.16); myohemoglobin (0.16); intrathoracic chemotherapy (0.16); doxorubicin toxicity (0.16); refractory (0.16) |
12 | 14 | 0.983 | 2000 | Cardiac surgery; extracorporeal life support; supraventricular tachycardia; extracorporeal membrane oxygenation; digoxin fab fragments | digoxin fab fragments; cardiac glycosides; cardiac surgery; extracorporeal life support; supraventricular tachycardia | (8.76, 0.005); supraventricular tachycardia (8.76, 0.005); toad venom (8.76, 0.005); cardenolides (8.76, 0.005); extracorporeal membrane oxygenation (8.76, 0.005) | Digoxin fab fragments (0.03); supraventricular tachycardia (0.03); toad venom (0.03); cardenolides (0.03); extracorporeal membrane oxygenation (0.03) |